Immunome, Inc.
IMNM
$15.67
-$0.82-4.97%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -4.22% | 48.11% | -70.38% | -30.39% | 72.10% |
Total Depreciation and Amortization | -0.83% | 22.02% | 4.20% | -15.16% | 155.89% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 3.03% | -84.88% | 219.07% | 10.21% | -91.91% |
Change in Net Operating Assets | 30.95% | -421.97% | 136.39% | -21.92% | -36.11% |
Cash from Operations | 6.89% | -26.14% | -23.10% | -46.03% | -109.46% |
Capital Expenditure | 75.31% | -166.55% | 97.11% | -1,931.78% | -8.32% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -822.71% | -21.37% | -84.48% | 190.39% | -126.26% |
Cash from Investing | -1,360.97% | -47.85% | -59.51% | 129.50% | -119.41% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -99.88% | 743.12% | 3,924.56% | -56.23% | -99.50% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 97.42% | -2,521.25% | -96.08% | 56.50% | 96.69% |
Cash from Financing | -100.03% | 707.71% | 6,485.25% | -56.05% | -99.68% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -199.44% | 1,035.27% | -25.12% | 90.65% | -161.03% |